|
ACI : Conference-Papers : 2005 : Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements
Structuring, Negotiating and Managing Win/WinPharma and Biotech In-Licensing, Co-Development and Co-Promotion AgreementsMonday, February 28, 2005
AboutDo you have the critical information and skills you need to structure, negotiate and manage successful partnerships to maintain a healthy product pipeline?In their efforts to fill depleted product pipelines, reduce development costs and leverage existing assets, virtually all pharmaceutical and biotech companies are increasingly relying on collaborations with each other and research institutions that include in-licensing, co-development and co-promotion arrangements. While these high-stakes collaborations can be highly profitable, they are also rife with potential misunderstandings and other minefields. It is imperative that in-house counsel, senior business executives and attorneys advising the pharmaceutical and biotech industries have an up-to-the-minute and in-depth understanding of the legal and business issues surrounding today's more complex partnerships and alliances so that these potential pitfalls can be avoided at the outset of the relationship. This American Conference Institute publication on In-Licensing, Co-Development and Co-Promotion Agreements will provide you with the tools and strategies you need to overcome the challenges of creating successful alliances and negotiating and drafting strategically effective agreements that can endure the twists and turns that occur over the long course of product discovery and development in the international marketplace. Contents & ContributorsAboutDo you have the critical information and skills you need to structure, negotiate and manage successful partnerships to maintain a healthy product pipeline?In their efforts to fill depleted product pipelines, reduce development costs and leverage existing assets, virtually all pharmaceutical and biotech companies are increasingly relying on collaborations with each other and research institutions that include in-licensing, co-development and co-promotion arrangements. While these high-stakes collaborations can be highly profitable, they are also rife with potential misunderstandings and other minefields. It is imperative that in-house counsel, senior business executives and attorneys advising the pharmaceutical and biotech industries have an up-to-the-minute and in-depth understanding of the legal and business issues surrounding today's more complex partnerships and alliances so that these potential pitfalls can be avoided at the outset of the relationship. This American Conference Institute publication on In-Licensing, Co-Development and Co-Promotion Agreements will provide you with the tools and strategies you need to overcome the challenges of creating successful alliances and negotiating and drafting strategically effective agreements that can endure the twists and turns that occur over the long course of product discovery and development in the international marketplace. Contents & ContributorsWHY THE TREND TO CO-DEVELOPMENT Susan Washer, Applied Genetics Technology Corporation STRATEGIC CONSIDERATIONS IN DETERMINING THE STRUCTURE AND GOVERNANCE FOR YOUR COLLABORATION Hemmie Chang, Ropes & Gray Phoebe Kornfeld, Chiron MAJOR CONSIDERATIONS IN NEGOTIATING AND DRAFTING PARTNERSHIPS DEALS Jerry Cohen, Cohen, Tauber, Spievack & Wagner LLP MAJOR CONSIDERATIONS IN NEGOTIATING AND DRAFTING PARTNERSHIPS DEALS Barclay Kamb, Cooley Godward LLP MAJOR CONSIDERATIONS IN NEGOTIATING AND DRAFTING PARTNERSHIPS DEALS – GOVERNANCE AND LEVELS OF DILIGENCE David Lawson, Gilead Sciences, Inc. IP ISSUES IN LATE STAGE TRANSACTIONSI Ralph Loren, Palmer & Dodge LLP GETTING TO DEAL CLOSING – A PRACTICAL CHECKLIST OF FOUNDATIONS FOR SUCCESSFUL COMPOUND OUT-LICENSING Eric Nelson, Nelson BioPartnering AN OVERVIEW OF THE EU'S TECHNOLOGY TRANSFER BLOCK EXEMPTION REGULATION David Hull, Covington & Burling HANDLING FDA RELATED ISSUES IN DRAFTING YOUR COLLABORATION AGREEMENTS Robert Dormer, Hyman, Phelps & McNamara, P.C. FDA ISSUES IN COLLABORATION AGREEMENTS – PRESERVING AND MAXIMIZING VALUE: ISSUES OF OWNERSHIP OF ACCESS AND COOPERATION Gregory Glover, Ropes & Gray ALTERNATE DEAL STRUCTURES: ADJUSTING YOUR PRODUCT PIPELINE THROUGH ACQUISITIONS, SPIN-OFFS AND DIVESTITURES Tom Bliss, Amgen Inc. Michael Flaschen, Amgen Inc. Stephen Johnson, Kirkland & Ellis COMMERCIALIZATION OF COLLABORATIVE PRODUCTS: PRACTICAL CONSIDERATIONS Benson Fong, Cotherix, Inc. CHALLENGES, PITFALLS AND ISSUES IN INTERNATIONAL COLLABORATIONS Kevin F. Kelly, Heller Ehrman White & McAuliffe LLP TAKING YOUR UNITED STATES AGREEMENT OVERSEAS: INTERNATIONAL CONCERNS IN IN-LICENSING, CO-DEVELOPMENT, AND CO-PROMOTION Joel Wolfson, Blank Rome LLP INTERNATIONAL CONCERNS IN AGREEMENTS Patricia Atkinson Roberts, Malaria Vaccine Initiative of PATH PRACTICAL AND ETHICAL STRATEGIES FOR NEGOTIATING AND DRAFTING "WIN-WIN" IN-LICENSING, CO-DEVELOPMENT AND CO-PROMOTION AGREEMENTS Jerry Cohen, Cohen, Tauber, Spievack & Wagner LLP Thomas Kowalski, Frommer Lawrence & Haug LLP Larry Tauber, Cohen, Tauber, Spievack & Wagner LLP |
Date: Mon, Feb 28, 2005 Location:
San Francisco, CA Pricing:
Option 1: Bundle Package
Binder & CD-ROM Save 299 - Best Value! Total: $699 + $9.95 (shipping & handling) + applicable taxes Option 2: CD-ROM
CD-ROM of program proceedings Total: $499 + $9.95 (shipping & handling) + applicable taxes Option 3: Binder
Printed copy of program proceedings Total: $499 + $9.95 (shipping & handling) |
 |
Publication Details |
Copyright 2007 C5 Group Inc. All Rights Reserved. |